2018-2021年武义县疑似预防接种异常反应监测结果  

Surveillance of suspected adverse events following immunization in Wuyi County from 2018 to 2021

作　　者：王晓柳[1] 汤元妃 WANG Xiaoliu;TANG Yuanfei(Department of Immunization Planning,Wuyi Center for Disease Control and Prevention,Wuyi,Zhejiang 321200,China)

机构地区：[1]武义县疾病预防控制中心免疫规划科,浙江武义321200

出　　处：《预防医学》2022年第11期1167-1171,1177,共6页CHINA PREVENTIVE MEDICINE JOURNAL

摘　　要：目的了解2018-2021年浙江省武义县疑似预防接种异常反应(AEFI)发生情况,为疫苗接种安全性评价提供依据。方法通过中国免疫规划信息管理系统AEFI信息管理系统和预防接种信息管理系统,收集2018-2021年武义县AEFI病例资料,采用描述性流行病学方法分析2018-2021年武义县AEFI报告发生率及AEFI病例特征。结果2018-2021年武义县共接种常规疫苗870007剂次,报告AEFI 482例,年均报告发生率为55.40/10万。免疫规划疫苗AEFI报告发生率为67.75/10万,高于非免疫规划疫苗的44.00/10万(χ^(2)=20.334,P<0.001)。一般反应435例,报告发生率为50.00/10万,主要表现为高热、局部红肿和硬结;异常反应39例,报告发生率为4.48/10万,过敏性反应占87.18%;偶合症7例;心因性反应1例;无疫苗质量事故和接种事故报告。AEFI报告发生率前五位疫苗为13价肺炎球菌多糖结合疫苗(269.11/10万)、无细胞百白破灭活脊灰和b型流感嗜血杆菌(结合)联合疫苗(204.23/10万)、23价肺炎球菌多糖疫苗(175.85/10万)、无细胞百白破联合疫苗(128.39/10万)、麻腮风联合减毒活疫苗(124.36/10万)。口服、皮内注射、皮下注射、肌内注射AEFI报告发生率分别为10.89/10万、49.88/10万、56.07/10万和57.78/10万。AEFI病例以0~<2岁为主,333例占69.09%。主要发生在接种后<1 d,336例占69.71%。结论2018—2021年武义县AEFI以一般反应为主,免疫规划疫苗AEFI报告发生率较非免疫规划疫苗要高,主要发生人群为2岁以下儿童。Objective To investigate the occurrence of suspected adverse events following immunization(AEFI)in Wuyi County,Zheijang Province from 2018 to 2021,so as to provide insights into safety assessment of vaccination.Methods The AEFI data in Wuyi County from 2018 to 2021 were collected from the AEFI Information Management System and Immunization Information Management System of National Immunization Information Management System in China.The reported incidence of AEFI and epidemiological characteristics of cases with AEFI were analyzed in Wuyi County from 2018 to 2021 using a descriptive epidemiological method.Results A total of 870007 vaccine doses had been adminis⁃tered in Wuyi County from 2018 to 2021,and a total of 482 AEFI were reported,with annual mean reported incidence of 55.40/105.The incidence of AEFI associated with vaccines included in the national immunization program was signifi⁃cantly higher than those not included in the national immunization program(67.75/105 vs.44.00/105;χ^(2)=20.334,P<0.001).There were 435 individuals with general reactions(50.00/105 incidence),with high fever,local redness and swell⁃ing and solid nodes;39 cases with abnormal reactions(4.48/105 incidence),including 87.18%allergic reactions;7 cases with coincident syndrome and one case with psychogenic reaction;however,no vaccine quality or vaccination events were reported.The five vaccines with the greatest incidence of AEFI included 13-valent pneumococcal polysaccharide conjugate vaccine(269.11/105),diphtheria and tetanus toxoids and acellular pertussis,inactivated poliovirus and Hae⁃mophilus b conjugate vaccine(204.23/105),23-valent pneumococcal polysaccharide vaccine(175.85/105),tetanus,diphtheria,acellular pertussis vaccine(128.39/105)and combined live vaccine for measles,mumps and rubella(124.36/105).The reported incidence rates of AEFI were 10.89/105,49.88/105,56.07/105 and 57.78/105 following oral,intradermal,subcuta⁃neous and intramuscular administrations,respectively.In addition,AEFI were predominantly found to oc

关 键 词：疑似预防接种异常反应 预防接种 监测 

分 类 号：R186[医药卫生—流行病学]